Subtype
Invasive Prostate Carcinoma
CI-CAN-00002961Explore in graph →
139 active trials1 approved drugs3 evidence items
- NCIt
- C48596
Loading cancer entity…
Subtype
CI-CAN-00002961Explore in graph →
Clinical trials
440 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01347788 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT01325311 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2016 | clinicaltrials |
| NCT00321646 | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 42 | Mary-Ellen Taplin, MDOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01219790 | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma(GEMO) | completed | Phase 1 | 30 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00438464 | Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery | completed | Phase 2 | 204 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00450229 | Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01898065 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer(HYPOXProstat) | completed | Phase 2 | 20 | Institut Cancerologie de l'OuestOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01011751 | Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma | completed | Phase 3 | 311 | TakedaINDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT01533246 | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00080899 | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00666666 | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00459407 | Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2014 | clinicaltrials |
| NCT02237612 | Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer | completed | N/A | 9 | University of Southern CaliforniaOTHER | 1 | Sep 11, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00087139 | Ixabepilone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00110214 | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 3 | 1,050 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | completed | Phase 2 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00016107 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00039104 | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00608920 | Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping(SPECT) | completed | N/A | 15 | Washington University School of MedicineOTHER | 1 | May 24, 2013 | clinicaltrials |
| NCT00182052 | Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer | completed | Phase 3 | 100 | Massachusetts General HospitalOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00502164 | Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer(AZD2171IL/0003) | completed | Phase 1 | 40 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
| NCT00181558 | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | completed | Phase 2 | 44 | Massachusetts General HospitalOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00379132 | 131-I-TM-601 Study in Adults With Solid Tumors | completed | Phase 1 | 60 | TransMolecularINDUSTRY | 1 | Mar 31, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Feb 23, 2017source: clinicaltrials